<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00274859</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000454320</org_study_id>
    <secondary_id>GERCOR-SEGEMOX-S04-1</secondary_id>
    <secondary_id>LILLY-GERCOR-SEGEMOX-S04-1</secondary_id>
    <secondary_id>SANOFI-GERCOR-SEGEMOX-S04-1</secondary_id>
    <secondary_id>EU-20571</secondary_id>
    <nct_id>NCT00274859</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Cancer</brief_title>
  <official_title>Multicenter Phase II Study Evaluating Gemcitabine and Oxaliplatin in the Treatment of Patients Suffering From Metastatic Breast Cancer Who Are Not Candidates For Treatment With Antracyclines and Taxanes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different
      ways to stop the growth of cancer cells, either by killing the cells or by stopping them from
      dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

      PURPOSE: This phase II trial is studying how well giving gemcitabine together with
      oxaliplatin works in treating patients with metastatic cancer who cannot receive
      anthracycline or taxane therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the objective response rate in patients with metastatic cancer not amenable to
           anthracycline or taxane therapy treated with gemcitabine hydrochloride and oxaliplatin.

      Secondary

        -  Determine the clinical benefit and tolerability of this regimen in these patients.

        -  Determine the progression-free and overall survival of patients treated with this
           regimen.

      OUTLINE: This is an open-label, multicenter study.

      Patients receive gemcitabine hydrochloride IV over 100 minutes on day 1 and oxaliplatin IV
      over 2 hours on day 2. Treatment repeats every 2 weeks in the absence of disease progression
      or unacceptable toxicity.

      After completion of study treatment, patients are followed periodically.

      PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2005</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed cancer

               -  Metastatic disease

          -  Measurable metastatic disease ≥ 1 cm by spiral CT scan and/or cutaneous lesion ≥ 2 cm

          -  Not a candidate for anthracycline or taxane chemotherapy

          -  No brain metastases

        PATIENT CHARACTERISTICS:

          -  ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

          -  Life expectancy &gt; 12 weeks

          -  Neutrophil count &gt; 1,000/mm^3

          -  Platelet count &gt; 100,000/mm^3

          -  Alkaline phosphatase &lt; 5 times upper limit of normal (ULN)

          -  Bilirubin &lt; 1.5 times ULN

          -  Creatinine &lt; 1.5 times ULN OR creatinine clearance &gt; 30 mL/min

          -  SGOT and SGPT &lt; 3 times ULN (5 times ULN if liver metastases present)

          -  No pre-existing neuropathy

          -  Not pregnant or nursing

          -  No uncontrolled hypercalcemia

          -  No familial, social, geographical, or psychological condition that would preclude
             study treatment

          -  No other malignancy that is not considered cured

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy for metastatic disease, including anthracyclines or taxanes

          -  Prior hormonal therapy allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Gligorov, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Tenon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>C.H.G. Beauvais</name>
      <address>
        <city>Beauvais</city>
        <zip>60021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Docteur Duchenne</name>
      <address>
        <city>Boulogne Sur Mer</city>
        <zip>62200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intercommunal Hospital</name>
      <address>
        <city>Montfermeil</city>
        <zip>93370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique De Courlancy</name>
      <address>
        <city>Reims</city>
        <zip>F-51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Saint-Quentin</name>
      <address>
        <city>Saint-Quentin</city>
        <zip>02321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. Senlis</name>
      <address>
        <city>Senlis</city>
        <zip>60309</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal Toulon - La Seyne Sur Mer</name>
      <address>
        <city>Toulon - Cedex</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2006</study_first_submitted>
  <study_first_submitted_qc>January 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2006</study_first_posted>
  <last_update_submitted>July 23, 2008</last_update_submitted>
  <last_update_submitted_qc>July 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2008</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

